In addition to the above therapies, other immunotherapies can be combined, such as combined cell therapy (MUC1-NK/T vaccine NCT04011033) in pancreatic cancer (51); The oncolytic viruses (OV) could be combined with direct lysis of cancer cells to release antigens and be equipped with immune-stimulating factors (such as IL-15/IL-18), initiating a cascade activation effect with the NK vaccine. Here, IL18 is linked to familial pancreatic carcinoma.